Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2025-10-03 00:00:00 ET · period of report 2025-10-01 · accession 0001801050-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-03 | 2025-10-01 | ARQT | Welgus Howard G. | Dir | M - OptEx | $1.68 | +9,538 | 109.7K | +10% | +$16.0K |
| DM | 2025-10-03 | 2025-10-01 | ARQT | Welgus Howard G. | Dir | S - Sale+OE | $18.92 | -10.0K | 100.2K | -9% | -$189.2K |
| D | 2025-10-03 | 2025-10-01 | ARQT | Welgus Howard G. | Dir | M - OptEx | $0.00 | -9,538 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-01 | M | A | 9,538 | $1.68 | 109,744 | D | — | — | |
| 2 | Common | Common Stock | 2025-10-01 | S | D | 462 | $18.92 | 99,744 | D | — | — | (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $18.84 to $19.038, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2025-10-01 | S | D | 9,538 | $18.92 | 100,206 | D | — | — | (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $18.84 to $19.038, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 4 | Derivative | Stock Option (right to buy) | 2025-10-01 | M | D | 9,538 | $0.00 | 0 | D | $1.68 · — to 2029-03-13 | 9,538 Common Stock | (F3) This option is fully vested. |